Biomarkers in heart failure

    Authors

    Abstract

    Over the past few years, we are witnessing a great progress in the treatment of heart failure (HF), as well as in the development of cardiac biomarkers. Intriguing interaction of various mechanisms, involving neurohumoral activation, inflammation, pressure/volume ventricular load, myocardial remodeling and myocardial lesion, lead to heart failure development. Natriuretic peptide testing is commonly used in routine clinical practice. It has a paramount role in the diagnosis and prognosis of HF as well as well-known significance in treatment-guided therapy. Knowing the complexity of HF pathophysiological process, new biomarkers have emerged that can replace the usual ones. (1-3) The aim of this paper is to compare natriuretic peptides, ST2, galectin-3, and highly sensitive troponin. It is reasonable to expect that the future will bring a multibiomarker panel as a necessary tool to improve HF understanding as well as better treatment of HF patients.

    Keywords

    biomarker, heart failure, NT-proBNP

    DOI

    https://doi.org/10.15836/ccar2018.352

    Literature

    1. Ibrahim NE, Januzzi JL. Established and Emerging Roles of Biomarkers in Heart Failure. Circ Res. 2018 Aug 17;123(5):614–29. https://doi.org/10.1161/CIRCRESAHA.118.312706
    2. Bošnjak I, Selthofer-Relatić K, Včev A. Prognostic Value of Galectin-3 in Patients with Heart Failure. Disease Markers. vol. 2015, Article ID 690205, 6pages, 2015. https://doi.org/10.1155/2015/690205
    3. Bošnjak I, Bedeković D, Selthofer-Relatić K, Bilić-Ćurčić I. Galectin-3: A Heart Failure Biomarker as Sign of Active Coronary Heart Disease. World J Cardiovasc Dis. 2017;7:373–9. https://doi.org/10.4236/wjcd.2017.711035
    Cardiologia Croatica
    Back to search

    Biomarkers in heart failure

    Extended Abstract
    Issue11-12
    Published
    Pages352
    PDF via DOIhttps://doi.org/10.15836/ccar2018.352
    biomarker
    heart failure
    NT-proBNP

    Authors

    Ivica Bošnjak*ORCIDKlinički bolnički centar Osijek, Osijek, Hrvatska
    Dražen BedekovićORCIDOpća županijska bolnica Našice, Našice, Hrvatska

    *Correspondence email: dribosnjak79@gmail.com

    Abstract

    Over the past few years, we are witnessing a great progress in the treatment of heart failure (HF), as well as in the development of cardiac biomarkers. Intriguing interaction of various mechanisms, involving neurohumoral activation, inflammation, pressure/volume ventricular load, myocardial remodeling and myocardial lesion, lead to heart failure development. Natriuretic peptide testing is commonly used in routine clinical practice. It has a paramount role in the diagnosis and prognosis of HF as well as well-known significance in treatment-guided therapy. Knowing the complexity of HF pathophysiological process, new biomarkers have emerged that can replace the usual ones. (1-3) The aim of this paper is to compare natriuretic peptides, ST2, galectin-3, and highly sensitive troponin. It is reasonable to expect that the future will bring a multibiomarker panel as a necessary tool to improve HF understanding as well as better treatment of HF patients.

    Literature

    1. 1.
      Ibrahim NE, Januzzi JL. Established and Emerging Roles of Biomarkers in Heart Failure. Circ Res. 2018 Aug 17;123(5):614–29.DOI
    2. 2.
      Bošnjak I, Selthofer-Relatić K, Včev A. Prognostic Value of Galectin-3 in Patients with Heart Failure. Disease Markers. vol. 2015, Article ID 690205, 6pages, 2015.DOI
    3. 3.
      Bošnjak I, Bedeković D, Selthofer-Relatić K, Bilić-Ćurčić I. Galectin-3: A Heart Failure Biomarker as Sign of Active Coronary Heart Disease. World J Cardiovasc Dis. 2017;7:373–9.DOI